MAPK1 and non-small cell lung carcinoma: The screen described here identified components of the RAS/MAPK pathway itself as among the strongest hits when combined with MEK inhibition in mutant KRAS NSCLC cells, including KRAS, RAF1 (encoding CRAF) and MAPK1 (encoding ERK2).